Store in original package until time of use. Argatroban: Discard product if it contains particulate matter, is cloudy, or discolored – Do not freeze – Protect from . Baxter U.S. – Healthcare Professionals – ARGATROBAN Injection in % Sodium Chloride mg/ mL (1 mg/1 mL). Argatroban is approved by the US Food and Drug Administration .. 51 to minutes), package insert recommendations provide guidance on.
|Published (Last):||18 April 2005|
|PDF File Size:||16.88 Mb|
|ePub File Size:||13.11 Mb|
|Price:||Free* [*Free Regsitration Required]|
Additionally, increased monitoring of the INR, especially during initiation and upon discontinuation of the antibiotic, may be necessary in patients receiving warfarin. The data of the ARG and ARG investigations provide convincing evidence that argatroban enables rapid and effective anticoagulation in this condition and is an effective therapy for HIT-associated complications.
Exembol Multidose causes a generally increased tendency to bleeding. Moderate Use caution with concomitant use of inotersen and anticoagulants due to the potential risk of bleeding from thrombocytopenia.
Update on argatroban for the prophylaxis and treatment of heparin-induced thrombocytopenia type II
Patients were randomized to receive a 4-week treatment period of either placebo or 3 or 6 grams of fish oil daily. Argatroban is a suitable regimen for use in renal replacement therapy RRTdue to the fact that it is mainly eliminated via the liver, and moreover dialytic clearance by high-flux membranes is considered clinically insignificant. The half-lives of lepirudin, danaparoid, and fondaparinux are approximately 80 argatorban, 24 hours, and 17—20 hours, respectively.
Monday – Friday 6: The increased bleeding risk with Exembol Multidose may constitute a risk in treatment during pregnancy. Argatroban excretion is primarily via the biliary tract. Thrombocytopenia usually occurs 5—14 days after first introduction of heparin therapy. Long-term concomitant treatment with edoxaban and other anticoagulants is not recommended; short-term use may be necessary for patients paclage to or from edoxaban.
If a patient requires anticoagulation after the procedure, argatroban may be continued at lower infusion dosages as those are recommended for patients with HIT or HITTS. Exembol Multidose is contraindicated in patients with severe hepatic impairment. Since ginkgo produces clinically-significant antiplatelet effects, it should be used cautiously in patients drugs that inhibit platelet aggregation or pose a risk for bleeding, such as anticoagulants.
Aminosalicylate sodium, Aminosalicylic acid: No initial dose regimen adjustment with respect to renal function is necessary. However, other published retrospective studies support the need to further reduce starting doses of argatroban to 0. Each vial contains 2.
Patients continued on heparin or argatroban for 48—72 hours or until angioplasty, at which point patients receiving argatroban were switched to heparin.
There is potential for combined effects on the INR with coadministration of argatroban and warfarin. The pharmacokinetics and pharmacodynamics of argatroban: Moderate Due to the risk of bleeding with natural antineoplastics, patients should receive other agents that may increase the risk of bleeding, such as anticoagulants. Moderate Because gastric ulceration and GI bleeding have been reported in patients taking deferasirox, use caution when coadministering with other drugs known to increase the risk of peptic ulcers or gastric hemorrhage including anticoagulants.
Currently available data are described in section 5.
[Full text] Update on argatroban for the prophylaxis and treatment of heparin-indu | JBM
inert The effect of argatroban on reproduction has been incompletely studied in animal experiments, as technical issues have limited systemic exposure see section 5. Limited data from a prospective clinical study in 18 children neonates to 16 years old and published data is available. Furthermore, in a case report published just recently, a year-old woman with severe HIT was treated with argatroban, and she had a positive clinical evolution with recovery of thrombocytopenia.
Important Risk Information Argatroban Injection is contraindicated in patients with major bleeding and patients with a history of hypersensitivity to Argatroban Discontinue all parenteral anticoagulants before administration of Argatroban Injection.
Limited data from postmarketing reports and published literature do not suggest an association between the use of argatroban and adverse fetal developmental outcomes. Steady-state anticoagulant effects are well correlated with steady-state plasma concentrations.
Major Platelet aggregation may be impaired by duloxetine due to platelet serotonin depletion, possibly increasing the risk of a bleeding complication e. Age is not a contraindication for the use of argatroban. For example, concurrent use of oxandrolone and warfarin may result in unexpectedly large increases in the INR or prothrombin time PT. Major Sulfinpyrazone should be avoided when possible with concurrent anticoagulants, thrombin inhibitors, and thrombolytic agents due to potential for increased bleeding risk.
The use of hypertonic sodium chloride in combination with tolvaptan may result in a too rapid correction of hyponatremia and increase the risk of osmotic demyelination i. In a limited number of patients, the hypoprothrombinemic response to warfarin was increased following large doses of vitamin A.
ACT should be checked 5 to 10 minutes after the bolus dose is completed.
Exembol Multidose 100 mg/ml concentrate for solution for infusion
Clear colourless to pale yellow solution. Argatroban in the management of heparin-induced thrombocytopenia.
The patients had a mean platelet count of All rights reserved Legal disclaimer Privacy Linking disclaimer. Infusions of argatroban should be gradually tapered in patients with unstable angina following initiation of aspirin or other antiplatelet agents.
However, there are exceptions, with HIT at times developing either early, namely after a recent previous exposure to heparin, or late after heparin exposure. If garlic dietary supplements are taken, monitor the INR or other appropriate parameters to attain clinical and anticoagulant endpoints. Carefully monitor sodium concentrations and fluid status if sodium-containing drugs and corticosteroids must be used together.
Supplemental oral sodium and fluid should be only be administered under careful medical supervision.
Qualitative and quantitative composition 3. The concomitant use of Exembol Multidose and oral anticoagulants of the coumarin type may result in prolongation of the PT INR beyond that produced by oral anticoagulants alone.
During the study period, thrombotic events occurred during argatroban infusion in 2 patients and after argatroban discontinuation in 3 other patients. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.